Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

Top venture syndicate invests to advance expanding pipeline of products to

treat ophthalmic diseases

PARIS, Dec. 12 /PRNewswire/ -- Fovea Pharmaceuticals SA, a biopharmaceutical company developing novel therapeutics for the treatment of ophthalmic diseases announced today that it raised EUR30M ($44M) in a Series B financing from a strong, international syndicate of new and existing investors led by Forbion Capital Partners (Naarden, The Netherlands). All existing institutional investors participated in the round including Sofinnova Partners, Abingworth, GIMV, The Wellcome Trust and CAPE.

Fovea plans to use the proceeds from this financing to advance its clinical and preclinical pipeline and further develop its technology platform. In 2008, Fovea expects to advance its FOV1101 program for chronic allergic conjunctivitis into phase 2 clinical trials and to initiate phase 2 studies of its FOV2302 and FOV2301 programs for the treatment of respectively acute and diabetic macular edema. The company expects to bring its fourth drug candidate, FOV2501, a protein discovered by Pr Jose-Alain Sahel's team (Inserm-UPMC U 592), into clinical trials in the first half of 2009.

"We are pleased that these leading investment firms recognize the value of Fovea's well balanced pipeline and unparalleled expertise in developing these novel therapies," said Bernard GILLY, Ph.D., Chairman and Chief Executive Officer of Fovea Pharmaceuticals. "The company has made enormous progress and this financing will enable us to continue to advance our lead programs through later-stage clinical studies."

"Forbion Capital Partners invests in biopharmaceutical companies pursuing first or best in class drugs. In particular, we focus on companies with strong domain expertise and experienced management. Fovea in our view is well positioned to become a leader in the ophthalmology field. We are impressed by how quickly they have built a highly promis
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
(Date:7/31/2014)... Researchers at Johns Hopkins have mapped the sound-processing part ... both the proverbial forest and the trees in view. ... views of brain activity within mice, and it enabled ... mice "called" to each other. The results, which represent ... process language, appear online July 31 the journal ...
(Date:7/31/2014)... 2014 Graphite Metallizing Corporation announces ... carts. These bearings are uniquely suited to prevent loss ... because of the high temperatures . , Recently, ... the design engineers at Graphite Metallizing to overcome problems ... their manufacturing operation, pans containing blocks of powder mixture ...
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
Breaking Biology Technology:Midwest Biotech Leaders Featured On BioSpace Map 2New mapping approach lets scientists zoom in and out as the brain processes sound 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... -- China Sky One Medical, Inc. ("China Sky One Medical" ... fully integrated pharmaceutical company in the People,s Republic of China ... Ren Medical Science and Technology Company ("TDR"), signed an agreement ... Tian Xin Biological Engineering Ltd. Harbin Tian ...
... Dec. 15, 2011  BioMed Realty Trust, Inc. (NYSE: ... declared a fourth quarter 2011 dividend of $0.20 per share ... dividend of $0.80 per common share. BioMed ... dividend of $0.46094 per share of the company,s 7.375% Series A ...
... 15, 2011 PDL BioPharma, Inc. (PDL) (NASDAQ: ... 15, 2011, regular quarterly dividend payment of $0.15 per share ... 8, 2011, the record date. (Logo: ... BioPharma PDL pioneered the humanization of monoclonal antibodies and, ...
Cached Biology Technology:China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise 2China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise 3BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends 2
(Date:7/31/2014)... France, and the U.S. has discovered and described ... member of the tribe Omaliini that has ever ... were made possible through the use of the ... the detailed study of otherwise invisible specimens in ... the journal Annals of the Entomological Society ...
(Date:7/31/2014)... percent of animal models against the highly infectious and ... intestinal disease that kills approximately 30,000 Americans annually. The ... and Immunity . , In the study, the ... purified toxins produced by C. difficile , as ... model that mimics the human disease, after only two ...
(Date:7/31/2014)... Prolonged exposure to loud noise alters how the ... distinguishing speech sounds, according to neuroscientists at The ... paper published this week in Ear and ... how noise-induced hearing loss affects the brain,s recognition ... reaches all corners of the population, affecting an ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2
... Based on a pilot study in children with sarcoma, ... that immunotherapy could prove beneficial in treating high-risk forms ... novel dendritic vaccine as well as a standard flu ... Their findings, published in the August 1 issue ...
... surprisingly simple, inexpensive technique, chemists have found a way ... amounts of electricity, common chemicals and a room-temperature glass ... fuels, many researchers have proposed using solar electricity to ... when the sun goes down. One of the chief ...
... NY In the United States, Lyme disease is ... from animals to humans. These animal-borne diseases can make ... and effective intervention are crucial to protecting the public. ... Millbrook, NY recently received $750,000 in grant funding from ...
Cached Biology News:Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2
...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Replacement Parts for Electrophoresis Apparatus...
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
Biology Products: